Combined Measurements of Cardiac Troponin I and Brain Natriuretic Peptide Are Useful for Predicting Adverse Outcomes in Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Combined Measurements of Cardiac Troponin I and Brain Natriuretic Peptide Are Useful for Predicting Adverse Outcomes in Hypertrophic Cardiomyopathy

Published:2011 Issue:4 Volume:75 Page:919-926
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Kubo Toru¹,Kitaoka Hiroaki¹,Okawa Makoto¹,Yamanaka Shigeo²,Hirota Takayoshi¹,Baba Yuichi¹,Hayato Kayo¹,Yamasaki Naohito¹,Matsumura Yoshihisa¹,Yasuda Nobufumi³,Sugiura Tetsuro²,Doi Yoshinori L.¹

Affiliation:

1. Department of Medicine and Geriatrics, Kochi Medical School

2. Department of Laboratory Medicine, Kochi Medical School

3. Department of Public Health, Kochi Medical School

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://www.jstage.jst.go.jp/article/circj/75/4/75_CJ-10-0782/_pdf

Reference25 articles.

1. 1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336: 775-785.

2. Hypertrophic Cardiomyopathy

3. 3. Kimura A. Molecular etiology and pathogenesis of hypertrophic cardiomyopathy. Circ J 2008; 72(Suppl A): A-38-A-48.

4. 4. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.

5. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy;Journal of the American College of Cardiology;2024-09

2. Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCM;European Journal of Heart Failure;2024-07-18

3. Plasma B-type natriuretic peptide is independently associated with cardiovascular events and mortality in patients with chronic kidney disease;Scientific Reports;2024-07-17

4. Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging;PLOS ONE;2024-04-18

5. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4;Journal of Cardiac Failure;2024-03